CERU News Alert Cerulean Pharma Inc. (CERU) 6.62 02/14/2015

New Post Public Reply Private Reply Replies (0) Message Board

Feb 14, 2015 at 9:32 PM

Cerulean Pharma Inc. (CERU) 6.62 $CERU

Nasdaq stocks posting largest percentage decreases
AP - Thu Feb 12, 5:04PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
PNTR: 7.90 (+0.01), INO: 6.80 (-0.15), HSKA: 20.95 (+0.07), JIVE: 5.34 (+0.02), CAKE: 48.22 (-1.04), CERU: 6.62 (-0.06), MKTO: 28.24 (+0.20), ANDE: 45.11 (+0.71), ZU: 14.22 (-0.30)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 11:45AM CST

CERU: 6.62 (-0.06), TBIO: 2.91 (+0.01), FXEN: 1.99 (+0.10), TRIP: 84.81 (+2.41), STMP: 56.92 (-0.24), ZEN: 25.38 (+1.02), OWW: 11.68 (-0.04), PME: 2.42 (-0.07), OESX: 4.15 (-0.01), GENE: 8.04 (+1.90), BG: 82.22 (+1.78), ARCI: 2.53 (-0.01), NTWK: 5.14 (-0.11), BASI: 2.06 (+0.18), EXPE: 89.49 (-0.08), MDWD: 7.22 (+0.17), SCOR: 53.35 (-1.10), LTRPA: 31.12 (+0.77), DWSN: 6.89 (-0.42), ZU: 14.22 (-0.30)

Cerulean to Present at Two Upcoming Conferences
Business Wire - Tue Feb 03, 7:02AM CST
Cerulean Pharma Inc. (Nasdaq:CERU), a leader in Dynamic Tumor Targeting(TM), today announced that Christopher D. T. Guiffre, JD, MBA, Chief Operating Officer, will present at the 7th Annual BIO CEO & Investor Conference in New York on Tuesday, February 10, 2015, at 9:30 a.m. ET. Mr. Guiffre also will participate in an analyst-led fireside chat at the Leerink Partners 2015 Global Healthcare Conference in New York on Thursday, February 12, 2015, at 1:00 p.m. ET.
CERU: 6.62 (-0.06)

Cerulean appoints Tiffany Crowell as VP of Clinical Operations
M2 - Fri Jan 30, 11:13PM CST
Tumor targeting company Cerulean Pharma (NasdaqGM:CERU) disclsoed on Thursday that Tiffany Crowell has been hired as vice president of its Clinical Operations.
CERU: 6.62 (-0.06)

Cerulean Appoints Vice President, Clinical Operations
Business Wire - Thu Jan 29, 7:03AM CST
Cerulean Pharma Inc. (Nasdaq: CERU), a leader in Dynamic Tumor Targeting(TM), today announced the appointment of Tiffany Crowell as Vice President, Clinical Operations.
CERU: 6.62 (-0.06)

CRLX101 Rectal Cancer Data Presented at ASCO 2015 Gastrointestinal Cancers Symposium
Business Wire - Mon Jan 19, 7:01AM CST
Cerulean Pharma Inc. (Nasdaq: CERU), a leader in Dynamic Tumor Targeting(TM), today announced that preclinical data and initial clinical data from a Phase 1b/2 investigator-sponsored trial of CRLX101 in combination with chemoradiotherapy in non-metastatic rectal cancer was presented at the ASCO 2015 Gastrointestinal Cancers Symposium held January 15-17, 2015.
CERU: 6.62 (-0.06)

Cerulean Secures Debt Facility from Hercules Technology Growth Capital of Up to $26.0 Million
Business Wire - Thu Jan 08, 3:00PM CST
Cerulean Pharma Inc. (Nasdaq: CERU), a leader in Dynamic Tumor Targeting(TM), today announced that it has entered into a loan and security agreement with Hercules Technology Growth Capital, Inc. (NYSE:HTGC) for a term loan of up to $26.0 million and completed a private placement for $1.0 million of Cerulean common stock with Hercules.
HTGC: 15.49 (+0.04), CERU: 6.62 (-0.06)

Cerulean Pharma (CERU) Worth a Look: Stock Rises 5.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jan 07, 7:30AM CST
Cerulean Pharma Inc. (CERU) was a big mover last session, as the company saw its shares rise over 5% on the day.
CERU: 6.62 (-0.06)

Cerulean Announces Publication Describing Synergistic Anti-Tumor Activity of CRLX101 with Avastin in Advanced Metastatic Ovarian Tumor Models
Business Wire - Tue Jan 06, 8:18AM CST
Cerulean Pharma Inc. (Nasdaq: CERU), a leader in Dynamic Tumor Targeting(TM), today announced that Clinical Cancer Research published a manuscript describing preclinical data demonstrating that CRLX101, Cerulean's proprietary investigational drug, has potent anti-tumor activity alone and in combination with Avastin(R) (bevacizumab) in advanced metastatic ovarian cancer.
CERU: 6.62 (-0.06)

Cerulean Announces First Patient Dosed with CRLX301 in Phase 1/2a Trial in Advanced Solid Tumors
Business Wire - Wed Dec 17, 7:30AM CST
Cerulean Pharma Inc. (Nasdaq: CERU), a leader in Dynamic Tumor Targeting(TM), today announced that the first patient has been dosed with CRLX301 in Cerulean's Phase 1/2a trial in patients with advanced solid tumor malignancies. CRLX301 is a nanoparticle-drug conjugate, or NDC, with a docetaxel payload, and it is the second clinical candidate from Cerulean's Dynamic Tumor Targeting Platform.
CERU: 6.62 (-0.06)

Cerulean Pharma (CERU): Strong Industry, Solid Earnings Estimate Revisions - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 8:07AM CST
One stock that might be an intriguing choice for investors right now is Cerulean Pharma Inc. (CERU)
CERU: 6.62 (-0.06)

Cerulean Pharma (CERU) Worth Watching: Stock Rises 16.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 15, 8:39AM CST
Cerulean Pharma Inc. (CERU) was a big mover last session, as its shares rose over 16% on the day.
LCI: 57.78 (-0.91), CERU: 6.62 (-0.06), SCMP: 15.32 (+0.04), IG: 10.57 (-0.12)

Cerulean Announces Completion of Enrollment of a Phase 1b/2 Study of CRLX101 in Combination with Avastin(R) in Relapsed Renal Cell Carcinoma
Business Wire - Mon Dec 15, 8:01AM CST
Cerulean Pharma Inc. (Nasdaq:CERU), a leader in Dynamic Tumor Targeting(TM), today announced completion of enrollment of 22 patients in a Phase 1b/2 clinical proof of principle trial of its lead nanoparticle-drug conjugate, CRLX101, in combination with Avastin(R) in relapsed renal cell carcinoma (RCC). This study is an investigator-sponsored trial (IST) being conducted by the University of Pennsylvania and Thomas Jefferson University Hospital with support from Cerulean. The Principal Investigator is Dr. Stephen Keefe of the University of Pennsylvania Abramson Cancer Center.
CERU: 6.62 (-0.06)

Cerulean beats by $0.12
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 4:48PM CST

CERU: 6.62 (-0.06)

Cerulean Reports Third-Quarter 2014 Corporate Highlights and Financial Results
GlobeNewswire - Thu Nov 13, 3:09PM CST
Cerulean Pharma Inc. (Nasdaq:CERU), a leader in Dynamic Tumor Targeting(TM), today provided an update on corporate activities during the quarter ended September 30, 2014.
CERU: 6.62 (-0.06)

Cerulean to Host Third-Quarter 2014 Conference Call on November 13
GlobeNewswire - Thu Oct 30, 7:01AM CDT
Cerulean Pharma Inc. (Nasdaq:CERU), a leader in Dynamic Tumor Targeting(TM), today announced it will provide an update on corporate activities for the third quarter of 2014 on November 13.
CERU: 6.62 (-0.06)

Cerulean Pharma elects Dr David Parkinson to board
M2 - Tue Oct 28, 8:11AM CDT
Dynamic tumor targeting company Cerulean Pharma (NasdaqGM:CERU) revealed on Monday that Dr David Parkinson, MD has joined its board of directors.
CERU: 6.62 (-0.06)

Cerulean Pharma Appoints David Parkinson, M.D., to Board of Directors
GlobeNewswire - Mon Oct 27, 3:02PM CDT
Cerulean Pharma Inc. (Nasdaq:CERU), a leader in Dynamic Tumor Targeting(TM), today announced the appointment of clinical oncology expert, David Parkinson, M.D., to its Board of Directors, effective as of October 29, 2014. With Dr. Parkinson's appointment, Cerulean has formed a Clinical Advisory Committee of the Board, which will consist of Dr. Parkinson, Dr. Susan Kelley and Dr. Paul Friedman.
CERU: 6.62 (-0.06)

Cerulean Announces Management Changes
GlobeNewswire - Mon Oct 27, 3:01PM CDT
Cerulean Pharma Inc. (Nasdaq:CERU), a leader in Dynamic Tumor Targeting(TM), today announced that Oliver Fetzer, Ph.D., has resigned as President and Chief Executive Officer, effective as of October 29, 2014, to pursue other professional opportunities. Paul Friedman, M.D., who currently serves on Cerulean's Board of Directors, will assume the position of Executive Chairman of the Board. Bill Rastetter, Ph.D., will continue to serve as the Lead Independent Director of the Board. Chris Guiffre, J.D., Cerulean's Chief Business Officer will assume the position of Chief Operating Officer. Dr. Fetzer will serve as a consultant to Cerulean through April of 2015.
CERU: 6.62 (-0.06)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

TechCrunch Disrupt 2026: NYSE and Snowflake Highlights

Ever noticed how the air vibrates just a bit more when major players like NYSE and Snowflake start shaking hands at big-league events like TechCrunch Disrupt? You'd better believe we're seeing a fresh brew of opportunities and challenges in the market as these titans lock horns and share insights. It's no small feat when the financial nerve center partners into the tech...

VetsinTech's AI Training Boosts Military Careers

A New Spin on Engineering Careers Sometimes it feels like every corner I turn in this market maze, there’s something about AI. It’s not just chirping in the tech world anymore; it’s banging on the doors of sectors like engineering, aerospace, and manufacturing. And now, VetsinTech is tossing its hat into the AI ring with a fresh program aimed at blending military...

Special Needs Group Partners with MAST to Enhance Accessibility

Accessible Travel Takes the Spotlight Ah, the travel biz—just when you think you’ve got it all figured out, along comes a partnership like this to shake things up. Special Needs Group, the big cheese in mobility and medical equipment rentals, is teaming up with MAST Travel Network. Together, they're rolling out initiatives to make the world a bit more accessible, even...

Coventry's Jacobs Joins European Life Settlement Execs

Neal Jacobs Steps Up in Life Settlements Coventry has added another feather to its cap with Neal Jacobs, their Senior Managing Director of Capital Markets, joining the Executive Committee of the European Life Settlement Association (ELSA). Elected at ELSA's Annual General Meeting on September 15, 2026, Jacobs brings a wealth of experience that promises to bolster the...

Skiptown Expands in Georgia Amid Growing Demand

With the pet care industry barking up a storm lately, Skiptown is ramping up efforts to expand its presence in Georgia. The tech-enabled dog care franchise already has a paw print in Atlanta, but it's sniffing out new opportunities across the state. Now they're on the hunt for franchise owners who can bring this modern approach to more communities. Why Georgia? The Growth...

Omneky Outshines Competitors in AI Ad Scoring

Brewing a better ad with AI isn't just about the model you plug in—it's about the wizardry wrapping around it. Omneky's latest caper in the AI advertising game has snagged the spotlight, pulling a hearty 8.8 taste score on a recent TasteBench comparison. That's not a minor tweak, folks, but a whopping 1.2-point lead over the shadow-chasing curves of the next...

Montessori and Tech: A New Era of Integration

Reimagining Montessori with Technology Let's take a stroll down the road less traveled—the intersection of Montessori education and tech. For over a century, Montessori schools have valued individual child development, autonomy, and a purpose-driven environment. But let's face it, their technology hasn't always had the same handcrafted finesse. That's where illumine...

Veterans Transitioning to Real Estate with Scholarships

Tapping Military Skills for Civilian Gain Finding a new career after military service is a mountain of a task, but veterans now have a golden ticket into the real estate appraisal world. The Appraisal Institute's Next Mission Scholarship is throwing veterans a $1,000 life preserver to dive into a field where their military-honed skills already shine. The Power of a...

AtWork Welcomes Franchise Vet Sarah Goehring

A Strategic Move for AtWork There's a new heavyweight at AtWork, a name that's been catching attention in the franchise biz lately—Sarah Goehring. This isn't just another appointment; it's a signal flare for AtWork's ambitions. With Goehring, they're doubling down on scaling their operation and drawing in more franchise players who are ready to hit the ground running....

Quark Baby's Milk Warmer Debut at Vancouver & Dubai

An Unconventional Pitch for Baby Gear Quark Baby is strutting its stuff not just in Vancouver but all the way in Dubai. Yeah, we're talking about a milk warmer hitting two major expos. What's the deal with an award-winning brand from Vancouver making so much noise? From October 17-18, they're home-court at The Baby Show Vancouver, and by October 22-24, they're in Dubai at...